The Biotech Business Model

Introduction

Biotech is fundamentally different from every other healthcare sub-sector. Big Pharma companies generate tens of billions in revenue from marketed products. Medical device companies sell hardware and consumables. Healthcare services companies bill for patient encounters. Biotech companies, particularly clinical-stage ones, generate zero product revenue for years or decades while spending $100-500 million per year on R&D. Their financial statements show nothing but losses, and yet some of these companies are worth billions.

This inversion, where a company's value comes entirely from what it might produce in the future rather than what it produces today, makes biotech the most analytically distinct sub-sector in healthcare banking. It requires different valuation tools (rNPV instead of DCF/multiples), different financial analysis (cash runway instead of earnings), and different M&A dynamics (acquirers paying for probability-weighted pipeline value, not current cash flow). This article establishes the foundational understanding of how biotech companies work, how they fund themselves, and why the distinction between platform and single-asset companies shapes every downstream analysis.

A clinical-stage biotech's income statement is the inverse of a normal company's. Where traditional companies show revenue at the top and profit at the bottom, a clinical-stage biotech shows minimal or zero revenue and escalating losses. This is not a sign of failure; it is the expected trajectory of a company investing in high-risk, high-reward drug development.

Reading a Biotech Income Statement

When analyzing a biotech income statement, the key items are not the traditional profitability metrics but the spend allocation and trend:

Revenue line. Clinical-stage biotechs may show small amounts of revenue from collaboration agreements (milestone payments, cost-sharing arrangements with partners), government grants, or small marketed products from earlier programs. This revenue is typically immaterial relative to the pipeline's potential value. What matters is the pipeline, not the revenue.

R&D expense breakdown. Sophisticated biotechs disclose R&D spending by program in their 10-K or investor presentations. This allows analysts to track how much capital is being directed toward each clinical program and to estimate remaining development costs. A biotech spending $150 million on its lead Phase III program and $30 million each on two earlier-stage programs gives much more pipeline visibility than one that reports a single aggregate R&D figure.

G&A expense. General and administrative costs (management compensation, legal, rent, insurance) typically represent 15-30% of total operating expenses. Unusually high G&A relative to R&D can signal management inefficiency or excessive compensation, while very low G&A can signal underinvestment in compliance, legal, or commercial preparation infrastructure.

Collaboration Revenue

Revenue recognized from partnership agreements with other pharmaceutical or biotech companies. Collaboration revenue includes upfront license payments (recognized over the collaboration period), milestone payments (recognized when milestones are achieved), cost-sharing reimbursements, and royalties on partner-commercialized products. Collaboration revenue can be lumpy (large milestones in certain quarters) and requires careful analysis of ASC 606 revenue recognition policies to understand timing. A biotech reporting $50 million in collaboration revenue is not necessarily generating sustainable recurring income; it may be recognizing a one-time milestone that will not recur.

Without product revenue, clinical-stage biotechs fund operations almost entirely through equity capital markets. The funding lifecycle follows a predictable pattern that maps to the clinical development stages:

Venture Capital

Venture capital funds the earliest stages (preclinical through early clinical). Series A/B/C rounds provide the capital to advance lead programs through initial clinical trials. VC rounds are typically $20-150 million and value the company based on the pipeline's potential, the team's track record, and the therapeutic opportunity.

Major biotech VCs operate differently from traditional technology VCs. Firms like Flagship Pioneering (which created Moderna), ARCH Venture Partners, OrbiMed, and RA Capital often take a hands-on approach: sitting on boards, recruiting management teams, and providing scientific guidance. Some (particularly Flagship) are company builders, creating biotechs from scratch around internal scientific ideas rather than waiting for entrepreneurs to pitch them.

IPO and the Public Markets

The biotech IPO provides the first public equity capital, typically when the company has Phase I or early Phase II data. Biotech IPOs are highly cyclical, clustering in bull markets and drying up in bear markets. The 2020-2021 window saw over 150 biotech IPOs in a two-year period; the 2022-2023 window saw far fewer as market conditions deteriorated.

IPO proceeds of $100-300 million fund the next stage of clinical development. The IPO also provides the company with public market currency (stock) that can be used for acquisitions, employee compensation, and future capital raises.

Follow-On Financing

Most biotech companies raise additional equity 2-4 times between IPO and approval. These raises include traditional follow-on offerings (underwritten secondary offerings), PIPEs (private investment in public equity, which became the dominant follow-on mechanism), ATM (at-the-market) programs that allow continuous share sales into the market, and convertible notes that provide debt-like financing with equity conversion features.

Each follow-on dilutes existing shareholders, creating a tension between the need for capital (to fund clinical development) and the desire to minimize dilution (to preserve shareholder value). This dilution calculus is central to biotech capital markets advisory.

Cash Runway

The number of months (or quarters) a biotech can continue operating at its current cash burn rate before exhausting its cash reserves. Cash runway is the single most important financial metric for clinical-stage biotechs. A company with 24+ months of runway has flexibility to execute its clinical plan without dilutive financing pressure. A company with less than 12 months faces urgent financing needs and may be forced to accept unfavorable deal terms (dilutive equity, distressed licensing, or sale). Healthcare bankers monitor cash runway as a primary indicator of a biotech's strategic optionality. The formula is straightforward: Cash and equivalents divided by quarterly cash burn rate equals quarters of runway.

Non-Dilutive Funding

Biotechs also pursue non-dilutive funding sources that do not require issuing equity:

The mix of dilutive and non-dilutive funding a biotech pursues has significant implications for shareholder value. A company that funds a $200 million Phase III trial entirely through equity offerings might dilute shareholders by 30-40%. One that combines a $100 million licensing upfront with a $100 million follow-on offering dilutes by only 15-20% while maintaining strategic optionality. Healthcare bankers advise on this funding mix as a core part of biotech capital markets strategy.

The most critical inflection point in a biotech's life cycle is the transition from clinical-stage (burning cash) to commercial-stage (generating revenue). This transition is far more complex than simply getting FDA approval.

Commercial infrastructure buildout. A biotech preparing for its first product launch must build a commercial organization from scratch: hiring a sales force (100-500+ representatives for a specialty product), establishing a medical affairs team, building market access and pricing capabilities, creating a distribution network, and standing up patient support programs. This buildout typically begins 12-18 months before expected approval and costs $50-150 million in advance of any revenue, accelerating the cash burn at the exact moment the company needs to conserve capital for launch.

The J-curve. Revenue from a new drug launch follows a J-curve: initial prescription volume builds slowly (physician awareness, prior authorization processes, formulary reviews), and the company incurs massive launch expenses before revenue ramps. Many biotechs see their operating losses actually increase in the first 6-12 months post-approval as launch spending exceeds early revenue. This creates a second period of financial vulnerability where the company may need additional capital despite having an approved product.

Biotech companies fall on a spectrum from pure single-asset companies to diversified platform companies. The distinction has significant implications for risk, valuation, and M&A dynamics.

Single-Asset Companies

A single-asset biotech has one lead program that represents substantially all of its value. These are the purest form of binary bet in healthcare:

Platform Companies

Platform biotechs have multiple pipeline assets across different stages, indications, or therapeutic modalities. This diversification reduces the binary risk of any single program but also dilutes the per-asset upside.

The Spectrum in Practice

Biotech companies do not operate in isolation. They exist within an ecosystem of capital providers, acquirers, partners, and service providers that shapes their strategic options at every stage:

Venture capital funds the earliest stages and provides scientific and strategic guidance. Major biotech VCs (Flagship Pioneering, ARCH Venture Partners, OrbiMed, RA Capital) are active company builders, not passive investors. The choice of VC investor often determines the company's strategic trajectory, management quality, and eventual exit path.

Big Pharma serves as both acquirer and partner. Over 60% of drugs approved by large pharma companies originate externally, often from biotech companies. The relationship is symbiotic: biotech innovates with higher risk tolerance and scientific agility, and pharma provides the commercial infrastructure (sales forces, market access teams, global distribution) and financial capacity to maximize the drug's commercial potential.

[Contract research organizations (CROs)](/guides/healthcare-investment-banking/cro-business-model) and contract development and manufacturing organizations (CDMOs) provide outsourced clinical trial management and drug manufacturing, allowing biotechs to operate with lean internal infrastructure. A clinical-stage biotech with 100 employees can run a global Phase III trial enrolling thousands of patients by outsourcing trial execution to a CRO like IQVIA or ICON.

Institutional investors (crossover funds, healthcare-focused hedge funds, long-only biotech funds) provide the equity capital that funds development. Specialized biotech investors bring scientific due diligence capabilities that generalist investors lack, enabling them to evaluate clinical data, assess probability of success, and price binary events.

Regulatory agencies (primarily the FDA) determine the evidentiary standards and development pathways that shape a biotech's cost, timeline, and probability of reaching the market. The regulatory strategy, including the pursuit of expedited pathways, orphan drug designation, or surrogate endpoints, is a strategic decision with significant financial implications.

Understanding the biotech business model is the foundation for the topics that follow: the biotech lifecycle and value inflection points, clinical trial mechanics, and the rNPV valuation methodology that is the core analytical tool for biotech banking.